Lankas GR, Leiting B, Roy RS, et al
The GLP-1 receptor exists primarily in the pancreas, stomach, and intestinesnot in the liver enzymes that metabolize most anticoagulants
Evidenztyp: Klinische Studie | Beobachtend | Tier | In vitro | Regulatorisch Mechanism of Action In Labormodellen wird berichtet, dass BPC-157 mit mehreren Signalwegen interagiert, die mit der Gewebeerhaltung und -reparatur in Verbindung stehen
Maridebart cafraglutide, combining GLP-1 receptor agonism with GIP receptor antagonism, exemplifies this innovative approach
Agonism of receptors in the gutpancreas axis in type 2 diabetes: Are two better than one
The Pipeline Continues to Evolve The approved oral options represent only the first generation of what is likely to be a rapidly developing field